Experts consider the method of stratification and current Cardiovascular assessment is not appropriate and should assess people without age limit.

– meeting the British model of cardiovascular protection, for their high rates of success has analyzed also as well as the rating system launched in this country of the cardiovascular risk without lage limit

– according to data presented within this day, cardiovascular mortality and selected risk factors control has improved in recent years in our country, but not so in others, as in the case of cholesterol

Madrid, 2013 February- medical clinical specialists in cardiovascular prevention and primary careEpidemiologists and professional managers have met last weekend to discuss the stratification of cardiovascular risk in Spain, review the situation of cardiovascular risk in our country, as well as to share and discuss the experience of the United Kingdom in terms of cardiovascular prevention, as a model of success in this area.

The Conference organized with the collaboration of the AstraZeneca biopharmaceutical company and the Association for the prevention of Cardiovascular risk (PRECAR), has counted with the presence of casts Spanish specialists as well as experts from the United Kingdom, directors of the Cardiovascular program in United Kingdom and consultants of the NICE (National Institute for health and clinical excellence in the United Kingdom)

during the sameone of the main issues discussed, it is the new approach to cardiovascular prevention includes people of all ages and that could change current guidelines of Cardiovascular Prevention in certain aspects.

Currently used only evaluation methodology is suitable in ages above age 60, people with a high risk of a cardiovascular event over the next ten years, period during which is the estimation of the chances of a patient to suffer an event or death by cardiovascular origin. However, young people are not considered because their level of risk will never reach values sufficiently high to make cost-effective drug treatment

explains doctor Luis Ruilope unit of hypertension of the Hospital 12 de octubre of Madrid therapeutic guidelines do not mark guidelines of action nor given treatment in people aged 40-45 This group can have no risks of having an event within this period ”. However, the doctor indicates that this population range has a risk of disease progress and between year ten and twenty suffer some kind of event or even die. In this sense, an assessment and consideration of younger subjects and therefore early action would prevent what could happen later ”.

In this regard, the doctor emphasizes that a cardiovascular event is not something that takes place in one or two years, but the process takes years. A person who has suffered a cardiovascular event at a late age, it most likely is that at an earlier age, for example 40-45 years, I had an affected kidney or cardiovascular system ”.

Cardiovascular risk stratification is a method recommended in all guides for the prevention and treatment of cardiovascular disease, its great informative face value to the decision making in the intervention in health education, measures higienico-dietetica, or drug treatment in order to reduce cardiovascular morbidity and mortality.

With regard to methods of stratification in Spain, it has been argued about Framingham (1) and Score (2) and the low implementation in our country. Doctor Ruilope referring to the Score, says one of the problems that presents is that it doesn’t note an important aspect as it is the organ damage and the presence of manifestations of this damage. For doctor Ruilope, would be the one used in hypertension, where the ideal table is put in relation the blood pressure levels in the presence and absence of factors of risk, diabetes, organ damage and established renal or cardiovascular disease ”.

Success rates in the British model of cardiovascular protection

The meeting analysed the British model of cardiovascular protection, for their high rates of success in the control of risk factors. In the case for example of the control of hypertension, more than ten years in the United Kingdom it was only 6-9%. On the contrary, now with the model and action guides has risen to 60% (3). Mortality has also declined, exceeding the expectations of the initial plan three or four years ahead of schedule.

Cholesterol, factors of risk to improve in our country

Within the same session, have been put on the table data on cardiovascular control in Spain based on a population survey conducted in 15,000 people (4), where it was noted that in Spain despite universal access to health systems, control of risk factors is less than expected. According to data, cardiovascular mortality and selected risk factors control has improved in recent years in our country, however not so in others, as in the case of cholesterol

and cardiovascular events are still the leading cause of death in Spainrepresenting one third of the total of all deaths.

About AstraZeneca